铋剂联合标准三联疗法根除幽门螺杆菌感染在超过90%患者中成功
基于欧洲幽门螺杆菌管理登记研究的多中心前瞻性数据,纳入1141例初治患者接受铋剂240mg联合含克拉霉素标准三联疗法(均每日两次)。意向治疗根除率88%,符合方案根除率94%;14天疗程意向治疗根除率升至93%。不良事件发生率36%,其中76%为轻度,平均持续6天。
要点
- 铋剂联合标准三联疗法意向治疗根除率88%,符合方案根除率94%。
- 14天疗程意向治疗根除率升至93%。
- 依从性(OR 13.0)、双倍剂量PPI(OR 4.7)、14天疗程(OR 2.0)与根除相关。
核心结论
- 在大型多中心登记研究数据分析中,铋剂加入14天含克拉霉素和amoxicillin标准三联疗法,基于意向治疗分析根除幽门螺杆菌感染超过90%患者,安全性和依从性可接受。
研究设计与样本
- 欧洲幽门螺杆菌管理登记研究(自2013年起注册欧洲27个国家感染患者临床数据与结局的前瞻性试验)的期中分析。
- 提取1141例初治患者,接受铋剂240mg、质子泵抑制剂(57%埃索美拉唑、18%奥美拉唑、11%泮托拉唑、14%雷贝拉唑)、amoxicillin 1g、克拉霉素500mg,均每日两次。
主要发现
- 意向治疗根除率88%,符合方案根除率94%。
- 接受14天治疗的患者意向治疗根除率升至93%。
- 不良事件发生率36%,其中76%为轻度,平均持续6天。
- 多变量分析中,根除与治疗依从性(OR 13.0)、双倍剂量(相当于奥美拉唑40mg)质子泵抑制剂(OR 4.7)、14天疗程(OR 2.0)相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Due to the poor eradication rates of standard triple therapy, the addition of bismuth salts has been proposed for first-line eradication of Helicobacter pylori. We assessed the effectiveness and safety of the combination of bismuth and the standard, clarithromycin-containing triple therapy in eradication of H pylori infection, using data from a large multi-center registry. METHODS: We performed an interim analysis of data from the European Registry on H pylori Management, a prospective trial registering clinical data and outcomes from infected patients from 27 countries in Europe since 2013. We extracted data on 1141 treatment-naïve patients who received first-line treatment with bismuth salts (240 mg) and a proton pump inhibitor (57% received esomeprazole, 18% received omeprazole, 11% received pantoprazole, and 14% received rabeprazole), amoxicillin (1 g), and clarithromycin (500 mg), all taken twice daily. RESULTS: Intention to treat and per-protocol rates of eradication were 88% and 94%, respectively. Intention to treat eradication increased to 93% in patients who received 14-day treatments. Adverse events occurred in 36% of patients; 76% of these events were mild, with a mean duration of 6 days. In multivariate analysis, eradication was associated with treatment compliance (odds ratio [OR], 13.0), a double dose (equivalent to 40 mg omeprazole) of proton pump inhibitor (OR, 4.7), and 14-day duration of treatment (OR, 2.0). CONCLUSIONS: In an analysis of data from a large multi-center registry, we found the addition of bismuth to 14-day standard triple therapy with clarithromycin and amoxicillin to eradicate H pylori infection in more than 90% of patients, based on intention to treat analysis, with an acceptable safety profile and level of adherence. ClinicalTrials.gov no: NCT02328131.
引用
- McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2019. PMID: 30978536. doi:10.1016/j.cgh.2019.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。